Neuraminidase inhibitors as antivirals.
The description of the three-dimensional structure of the influenza virus neuraminidase in 1983 opened a new phase in the search for inhibitors of the enzyme. Two compounds in late development (February 1999) have similar levels of potency against influenza A viruses, different routes of administration and, surprisingly, different resistance profiles both in vitro and in vivo.
Walter and Eliza Hall Institute of Medical Research, P.O. Royal Melbourne Hospital, Melbourne, Vic. 3050, Australia. pcolman@wehi.edu.au
P M
PM
Colman
D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects*; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D011714:Pyrans; D012794:Sialic Acids / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D053243:Zanamivir
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir